Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2020 | Impact of ruxolitinib approval on myelofibrosis real-world survival in the US

Srdan Verstovsek • 11 Jun 2020
EHA 2020
Myelofibrosis Myeloproliferative Neoplasms Ruxolitinib

Srdan Verstovsek, MD, PhD, of the University of Texas MD Anderson Cancer Center, Houston, TX, outlines the impact of ruxolitinib’s approval in 2011 on real-world data of elderly myelofibrosis patients in the United States. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Srdan Verstovsek

An update on the use of navtemadlin in myelofibrosis 1:52
An update on the use of navtemadlin in myelofibrosis
Srdan Verstovsek • 7 Dec 2022
Insights into the Phase IIa Mylox-1 trial: assessing efficacy of GB2064 in myelofibrosis 2:19
Insights into the Phase IIa Mylox-1 trial: assessing efficacy of GB2064 in myelofibrosis
Srdan Verstovsek • 7 Dec 2022
FIGHT-203 trial: pemigatinib in patients with MLNs with FGFR1 rearrangement 2:19
FIGHT-203 trial: pemigatinib in patients with MLNs with FGFR1 rearrangement
Srdan Verstovsek • 7 Dec 2022
Rationale for VERIFY: rusfertide added to ongoing therapy in patients with polycythemia vera 1:56
Rationale for VERIFY: rusfertide added to ongoing therapy in patients with polycythemia vera
Srdan Verstovsek • 7 Dec 2022

Related Videos

Patient-reported outcomes in the Phase III VERIFY trial of rusfertide for polycythemia vera 2:04
Patient-reported outcomes in the Phase III VERIFY trial of rusfertide for polycythemia vera
Aniket Bankar • 8 Dec 2025
12-month primary endpoint analysis from the Phase III ROP-ET study of ropeginterferon alfa-2b in ET 2:25
12-month primary endpoint analysis from the Phase III ROP-ET study of ropeginterferon alfa-2b in ET
Jean-Jacques Kiladjian • 8 Dec 2025
Genome editing for treatment of JAK2 V617F-driven myeloproliferative neoplasms 1:39
Genome editing for treatment of JAK2 V617F-driven myeloproliferative neoplasms
Roman Doll • 7 Dec 2025
Using artificial intelligence to accelerate patient eligibility screening in clinical trials 1:52
Using artificial intelligence to accelerate patient eligibility screening in clinical trials
Aaron Gerds • 5 Dec 2025
The content of VJHemOnc is intended for healthcare professionals